The enzyme as drug: application of enzymes as pharmaceuticals (Q35207853)

7 August 2017

1 reference

title

The enzyme as drug: application of enzymes as pharmaceuticals (English)

1 reference

7 August 2017

Michel Vellard

1

1 reference

7 August 2017

publication date

1 August 2003

1 reference

Current Opinion in Biotechnology

7 August 2017

published in

1 reference

7 August 2017

volume

14

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

444-450

1 reference

PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

PEG drugs: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Chemistry for peptide and protein PEGylation

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Fabry disease: recent advances in enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Enzyme replacement therapy for the mucopolysaccharide storage disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Enzyme-replacement therapy in mucopolysaccharidosis I.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Sacrosidase therapy for congenital sucrase-isomaltase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Proper usage of pancreatic enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Structural basis for gluten intolerance in celiac sprue

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Dornase alfa in early cystic fibrosis lung disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

A review on the nonoperative removal of necrotic tissue from burn wounds

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Varidase: the science behind the medicament

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Enzymatic debridement of burn wound with collagenase in children with partial-thickness burns

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Chondroitinase ABC promotes functional recovery after spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Limited growth of severed CNS axons after treatment of adult rat brain with hyaluronidase

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

A bacteriolytic agent that detects and kills Bacillus anthracis

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

The murein hydrolase of the bacteriophage phi3626 dual lysis system is active against all tested Clostridium perfringens strains

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962)

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Development of a genetic system for the transfer of DNA into Flavobacterium heparinum

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Expression system for high levels of GAG lyase gene expression and study of the hepA upstream region in Flavobacterium heparinum

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Rasburicase: a potent uricolytic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Extension of Life-Span with Superoxide Dismutase/Catalase Mimetics

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Superoxide dismutase mimetics with catalase activity reduce the organ injury in hemorrhagic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Re-engineering butyrylcholinesterase as a cocaine hydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

Towards novel processes for the fine-chemical and pharmaceutical industries

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900092-2

7 January 2021

10.1016/S0958-1669(03)00092-2

Identifiers

DOI

1 reference

7 August 2017

1 reference